Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies.
Nicole ViveirosBianca de Cássia Troncarelli FloresJoão LoboCláudia Martins-LimaMariana CantantePaula LopesCecilia DeantonioCintia PaluRichard C A SainsonRui M HenriqueCarmen JerónimoPublished in: Clinical & translational immunology (2022)
Immune infiltrates of HG NMIBC and MIBC display significant differences that may help selecting patients for immunotherapies. Considering ICOS immunoexpression results, it might constitute a relevant therapeutic target, eventually in combination with anti-PD-1/PD-L1 therapies, for certain BlCa patient subsets.